Klodeta Kura1,2,3, Diepreye Ayabina4, Jaspreet Toor4, T Deirdre Hollingsworth4, Roy M Anderson1,2,3,5. 1. London Centre for Neglected Tropical Disease Research, London, UK. 2. Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary's Campus, Imperial College London, London, UK. 3. MRC Centre for Global Infectious Disease Analysis. 4. Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7LF, UK. 5. DeWorm3 Project, Natural History Museum of London, London, UK.
Abstract
BACKGROUND: The 2030 goal for schistosomiasis is elimination as a public health problem (EPHP), with mass drug administration (MDA) of praziquantel to school-age children (SAC) as a central pillar of the strategy. However, due to coronavirus disease 2019, many mass treatment campaigns for schistosomiasis have been halted, with uncertain implications for the programmes. METHODS: We use mathematical modelling to explore how postponement of MDA and various mitigation strategies affect achievement of the EPHP goal for Schistosoma mansoni and S. haematobium. RESULTS: For both S. mansoni and S. haematobium in moderate- and some high-prevalence settings, the disruption may delay the goal by up to 2 y. In some high-prevalence settings, EPHP is not achievable with current strategies and so the disruption will not impact this. Here, increasing SAC coverage and treating adults can achieve the goal. The impact of MDA disruption and the appropriate mitigation strategy varies according to the baseline prevalence prior to treatment, the burden of infection in adults and the stage of the programme. CONCLUSIONS: Schistosomiasis MDA programmes in medium- and high-prevalence areas should restart as soon as is feasible and mitigation strategies may be required in some settings.
BACKGROUND: The 2030 goal for schistosomiasis is elimination as a public health problem (EPHP), with mass drug administration (MDA) of praziquantel to school-age children (SAC) as a central pillar of the strategy. However, due to coronavirus disease 2019, many mass treatment campaigns for schistosomiasis have been halted, with uncertain implications for the programmes. METHODS: We use mathematical modelling to explore how postponement of MDA and various mitigation strategies affect achievement of the EPHP goal for Schistosoma mansoni and S. haematobium. RESULTS: For both S. mansoni and S. haematobium in moderate- and some high-prevalence settings, the disruption may delay the goal by up to 2 y. In some high-prevalence settings, EPHP is not achievable with current strategies and so the disruption will not impact this. Here, increasing SAC coverage and treating adults can achieve the goal. The impact of MDA disruption and the appropriate mitigation strategy varies according to the baseline prevalence prior to treatment, the burden of infection in adults and the stage of the programme. CONCLUSIONS:Schistosomiasis MDA programmes in medium- and high-prevalence areas should restart as soon as is feasible and mitigation strategies may be required in some settings.
Authors: Anna Borlase; Epke A Le Rutte; Soledad Castaño; David J Blok; Jaspreet Toor; Federica Giardina; Emma L Davis Journal: Lancet Glob Health Date: 2022-11 Impact factor: 38.927
Authors: Mariana do Rosário Souza; Wandklebson Silva da Paz; Vinícius Barbosa Dos Santos Sales; Gleidson Felipe Hilario de Jesus; Débora Dos Santos Tavares; Shirley V M Almeida Lima; Álvaro Francisco Lopes Sousa; Enaldo Vieira de Melo; Rodrigo Feliciano do Carmo; Carlos Dornels Freire de Souza; Márcio Bezerra-Santos Journal: Front Pharmacol Date: 2022-06-29 Impact factor: 5.988
Authors: Wandklebson Silva da Paz; Mariana do Rosário Souza; Débora Dos Santos Tavares; Amélia Ribeiro de Jesus; Allan Dantas Dos Santos; Rodrigo Feliciano do Carmo; Carlos Dornels Freire de Souza; Márcio Bezerra-Santos Journal: Lancet Reg Health Am Date: 2022-01-15
Authors: Wandklebson Silva da Paz; Erica Dos Santos Reis; Iane Brito Leal; Yanna Menezes Barbosa; Karina Conceição Gm de Araújo; Amélia Ribeiro de Jesus; Carlos Dornels Freire de Souza; Allan Dantas Dos Santos; Márcio Bezerra-Santos Journal: J Glob Health Date: 2021-10-09 Impact factor: 4.413
Authors: Jessica Clark; Wilma A Stolk; María-Gloria Basáñez; Luc E Coffeng; Zulma M Cucunubá; Matthew A Dixon; Louise Dyson; Katie Hampson; Michael Marks; Graham F Medley; Timothy M Pollington; Joaquin M Prada; Kat S Rock; Henrik Salje; Jaspreet Toor; T Déirdre Hollingsworth Journal: Gates Open Res Date: 2022-02-02
Authors: Raquel Sánchez-Marqués; Santiago Mas-Coma; Joaquín Salas-Coronas; Jerôme Boissier; María Dolores Bargues Journal: Int J Environ Res Public Health Date: 2022-06-30 Impact factor: 4.614
Authors: T Déirdre Hollingsworth; Pauline Mwinzi; Andreia Vasconcelos; Sake J de Vlas Journal: Trans R Soc Trop Med Hyg Date: 2021-03-06 Impact factor: 2.184